Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of the reSept ASD Occluder to Treat Patients With Clinically Significant Secundum Atrial Septal Defect

NCT04591392 is registered in ClinicalTrials.gov with atHeart Medical as lead sponsor.

NCT NCT04591392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04591392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of the reSept ASD Occluder to Treat Patients With Clinically Significant Secundum Atrial Septal Defect
Lead sponsor
atHeart Medical
Phase
Not applicable
Overall status
Active, not recruiting
Start date
March 12, 2021
Completion date
March 31, 2032
Enrollment
250 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular abnormalities, cardiovascular diseases, congenital abnormalities, heart defects, congenital, heart diseases, heart septal defect, heart septal defects, atrial